Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 32887873

Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Blood Cancer J
Publication date
2020 Sep 4
First author
Dimopoulos MA

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships

    Authors and identifiers

    1. name
      Dimopoulos MA
      type
      Author
    2. name
      Lonial S
      type
      Author
    3. name
      White D
      type
      Author
    4. name
      Moreau P
      type
      Author
    5. name
      Weisel K
      type
      Author
    6. name
      San-Miguel J
      type
      Author
    7. name
      Shpilberg O
      type
      Author
    8. name
      Grosicki S
      type
      Author
    9. name
      Špička I
      type
      Author
    10. name
      Walter-Croneck A
      type
      Author
    11. name
      Magen H
      type
      Author
    12. name
      Mateos MV
      type
      Author
    Complete bibliographic record and source provenance
    authors
    1. name
      Dimopoulos MA
      type
      Author
    2. name
      Lonial S
      type
      Author
    3. name
      White D
      type
      Author
    4. name
      Moreau P
      type
      Author
    5. name
      Weisel K
      type
      Author
    6. name
      San-Miguel J
      type
      Author
    7. name
      Shpilberg O
      type
      Author
    8. name
      Grosicki S
      type
      Author
    9. name
      Špička I
      type
      Author
    10. name
      Walter-Croneck A
      type
      Author
    11. name
      Magen H
      type
      Author
    12. name
      Mateos MV
      type
      Author
    bibliography ids
    1. nci-bib-ab32f2a4d599dd5c52228425
    book metadata
    content sha256
    8e8a8cd1a6b72cabc0c04af2a41f0818be65406dce19ccc4af0f0ff5668123bc
    document type
    citation
    dois
    1. 10.1038/s41408-020-00357-4
    electronic publication date
    display
    2020 Sep 4
    precision
    day
    year
    2020
    evidence scope
    bibliographic_metadata_only
    id
    pubmed:32887873
    immutable id
    pubmed:32887873@8e8a8cd1a6b72cabc0c04af2a41f0818be65406dce19ccc4af0f0ff5668123bc
    journal
    abbreviation
    Blood Cancer J
    issn electronic
    2044-5385
    issn print
    Source null
    issue
    9
    name
    Blood cancer journal
    nlm unique id
    101568469
    pages
    91
    volume
    10
    languages
    1. eng
    notices
    absence is not clearance
    true
    has correction metadata
    false
    has expression of concern metadata
    false
    has retraction in link
    false
    pubmed marks article retracted
    false
    pubmed marks retraction notice
    false
    relationships
      outcomes validated
      false
      pmid
      32887873
      provenance
      batch id
      9bca82d1bba2b27adc79
      provider
      NCBI PubMed ESummary
      record sha256
      69c2b849786f853a39acd2bf57a3420d3646d04d933a0765a65248470d1ddaf5
      response sha256
      c8a4853c65a45038af15f5ade3970763bfa121cf5c68bafcc52c3a06860d0211
      retrieved at
      2026-09-09T23:47:56.131551+00:00
      publication date
      display
      2020 Sep 4
      precision
      day
      year
      2020
      publication types
      1. Clinical Trial, Phase III
      2. Journal Article
      3. Multicenter Study
      4. Randomized Controlled Trial
      5. Research Support, Non-U.S. Gov't
      record status
      PubMed - indexed for MEDLINE
      schema version
      1.0
      source url
      https://pubmed.ncbi.nlm.nih.gov/32887873/
      title
      Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study.

      Preserved source evidence · Not medical advice